Preliminary outcomes are reported for 202 patients with Tlc prostate c
ancer treated with three-dimensional conformal radiation treatment (3D
CRT). At 5 years, actuarial freedom from failure is demonstrated in 97
% of patients with pretreatment PSA levels of <10 ng/ml, in 88% of tho
se with PSA levels of 10-19.9 ng/ml, and in 91% of young patients (les
s than or equal to 65 years) with PSA levels of <20 ng/ml. The late mo
rbidity following this technology is extremely favorable, with <1% of
patients developing serious GI sequelae, <1% using a daily pad for inc
ontinence, and 61% maintaining sexual potency. Continued development a
nd use of 3DCRT technology is indicated for patients who elect externa
l beam radiation treatment.